Scientia Vascular, Inc.

Scientia Vascular LLC, based in West Valley City, Utah, develops advanced neurovascular treatment systems including guidewires and catheters, enhancing precision in therapeutic interventions for neurovascular diseases. Scientia Vascular LLC focuses on creating solutions for neurovascular interventions, founded in 2007 in West Valley City, US. Scientia Vascular specializes in the development of advanced neurovascular treatment systems, primarily focusing on guidewires and catheters. Their flagship products, such as the Aristotle series of guidewires and Socrates microcatheters, leverage a patented microfabrication process that enhances navigation through the brain's complex neurovasculature.

These products are designed to provide quicker therapy delivery with increased precision and deeper access during neurovascular interventions. Targeted towards healthcare professionals and facilities that specialize in treating neurovascular diseases, Scientia Vascular aims to serve hospitals and medical practices looking for innovative solutions in neurointerventional procedures. Their products are marketed primarily in North America, with potential interests in expanding to other regions where specialized neurovascular treatment solutions are in demand. Scientia Vascular generates revenue through direct sales of its specialized medical products, including guidewires and catheters, to healthcare providers and institutions.

The typical transaction structure involves B2B sales, where hospitals and medical facilities purchase these products for use in therapeutic procedures. Pricing plans for their offerings are set according to the specific needs of healthcare professionals, with costs determined by the customization and specifications of the products ordered. By focusing on partnerships with medical facilities, Scientia Vascular establishes a reliable revenue stream while ensuring that their advanced neurovascular technologies are readily accessible to end-users. The company’s continued growth and innovation in product development aim to enhance its market position and revenue potential within the healthcare landscape.

The company is focused on developing upcoming products designed to improve neurovascular treatment efficacy and is exploring expansion into new markets, particularly in regions with rising demand for specialized neurovascular solutions. In March 2026, Medtronic plc, a portfolio company of Blackstone, agreed to acquire Scientia Vascular, Inc. from Piper Sandler and Vivo Capital for USD 550 million. This transaction is expected to be completed in the first half of FY27 and is subject to regulatory approvals and other closing conditions.